| Name | DSR-6434 |
| Description | DSR-6434 is a selective agonist of TLR7 with antitumor effect. DSR-6434 exhibits EC50s of 7.2 nM and 4.6 nM for human and mouse. |
| In vitro | To evaluate the specificity of DSR-6434 for TLR7, a NF-κB-driven reporter assay was conducted in HEK293 cells engineered to express hTLR7, TLR8, or TLR9. This assay determines specificity through NF-κB activation upon successful receptor binding. Results demonstrate that DSR-6434 selectively stimulates reporter gene activity in cells expressing hTLR7, but not in those expressing the structurally similar hTLR8 or hTLR9[1]. |
| In vivo | In B6C3F1 mice, DSR-6434 (0.1-1 mg/kg; i.v.) significantly suppresses lung metastasis[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 5 mg/mL (12.49 mM), Sonication is recommended.
DMSO : 225 mg/mL (561.83 mM), Sonication is recommended.
|
| Keywords | TLR7 | DSR-6434 | DSR6434 | DSR 6434 |
| Inhibitors Related | D-Glucuronic acid | Hydroxychloroquine | Benzyl alcohol | (±)-Naringenin | Chloroquine phosphate | Chloranil | CU-115 | Thiamine hydrochloride | 2,4,5-Trimethoxybenzoic acid | Resiquimod | Stevioside | DHBP |
| Related Compound Libraries | NF-κB Signaling Compound Library | Bioactive Compound Library | Anti-Alzheimer's Disease Compound Library | Membrane Protein-targeted Compound Library | HIF-1 Signaling Pathway Compound Library | Antioxidant Compound Library | Immuno-Oncology Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
United States
